By Scientia Professor Vlado Perkovic

Journal articles

Perkovic V; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Dimino TL; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; Mcmurray JJV; Meadowcroft AM; Obrador GT; Solomon S; Taft L; Wanner C; Waikar SS; Wheeler DC; Wiecek A; Singh AK, 2022, 'The ASCEND-ND trial: study design and participant characteristics', Nephrology Dialysis Transplantation, 37, pp. 2157 - 2170, http://dx.doi.org/10.1093/ndt/gfab318

Mahaffey KW; Baeres FMM; Bakris G; Bosch-Traberg H; Gislum M; Lawson J; Mann JFE; Mersebach H; Perkovic V; Rossing P; Tuttle K; Pratley R, 2022, 'Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.2617

Singh AK; Acharya A; Carroll K; Lopes RD; McCausland FR; Mulloy L; Perkovic V; Solomon S; Waikar SS; Wanner C; Wong MG; Cobitz AR; Mallett SA; Shaddinger BC; McMurray JJV, 2022, 'Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.1053

McCausland F; Singh A; Claggett B; Carroll K; Wittes J; McMurray JJV; Perkovic V; Snappin S; Lopes R; Solomon S, 2022, 'Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.2621

Li C; Yu J; Hockham C; Perkovic V; Neuen BL; Badve SV; Houston L; Lee VYJ; Barraclough JY; Fletcher RA; Mahaffey KW; Heerspink HJL; Cannon CP; Neal B; Arnott C, 2022, 'Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis', Diabetes, Obesity and Metabolism, 24, pp. 1927 - 1938, http://dx.doi.org/10.1111/dom.14772

Wong MG; Lv J; Perkovic V, 2022, 'Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy - Reply', JAMA, 328, pp. 1108 - 1109, http://dx.doi.org/10.1001/jama.2022.12712

Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K; Agodoa L; Algra A; Asselbergs FW; Beckett N; Berge E; Black H; Brouwers FPJ; Brown M; Bulpitt CJ; Byington B; Cutler J; Devereaux RB; Dwyer J; Estacio R; Fagard R; Fox K; Fukui T; Imai Y; Ishii M; Julius S; Kanno Y; Kjeldsen SE; Kostis J; Kuramoto K; Lanke J; Lewis E; Lewis J; Lievre M; Lindholm LH; Lueders S; MacMahon S; Mancia G; Matsuzaki M; Mehlum MH; Nissen S; Ogawa H; Ogihara T; Ohkubo T; Palmer C; Patel A; Pfeffer M; Poulter NR; Rakugi H; Reboldi G; Reid C; Remuzzi G; Ruggenenti P; Saruta T; Schrader J; Schrier R; Sever P; Sleight P; Staessen JA; Suzuki H; Thijs L; Ueshima K; Umemoto S; van Gilst WH; Verdecchia P; Wachtell K; Whelton P; Wing L; Yui Y; Yusuf S; Zanchetti A; Zhang ZY; Anderson C; Baigent C; Brenner BM; Collins R; de Zeeuw D; Lubsen J; Malacco E; Neal B; Perkovic V; Pitt B; Rodgers A; Rothwell P; Salimi-Khorshidi G; Sundström J, 2022, 'Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis', The Lancet Diabetes and Endocrinology, 10, pp. 645 - 654, http://dx.doi.org/10.1016/S2213-8587(22)00172-3

Li JW; Arnott C; Heerspink HJL; Mbiostat QL; Cannon CP; Wheeler DC; Charytan DM; Barraclough J; Figtree GA; Agarwal R; Bakris G; de Zeeuw D; Greene T; Levin A; Pollock C; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Neal B; Jardine MJ, 2022, 'Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial', Journal of the American Heart Association, 11, pp. e025045, http://dx.doi.org/10.1161/JAHA.121.025045

Ferrannini E; Baldi S; Scozzaro T; Tsimihodimos V; Tesfaye F; Shaw W; Rosenthal N; Figtree GA; Neal B; Mahaffey KW; Perkovic V; Hansen MK, 2022, 'Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)', Diabetes Care, 45, pp. 1893 - 1899, http://dx.doi.org/10.2337/dc21-2398

Heerspink HJL; Stack AG; Terkeltaub R; Greene TA; Inker LA; Bjursell M; Perl S; Rikte T; Erlandsson F; Perkovic V, 2022, 'Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia', Nephrology Dialysis Transplantation, 37, pp. 1461 - 1471, http://dx.doi.org/10.1093/ndt/gfab237

Smeijer JD; Koomen J; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Januzzi JL; Kitzman DW; Kolansky DM; Makino H; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL, 2022, 'Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure', JACC: Heart Failure, 10, pp. 498 - 507, http://dx.doi.org/10.1016/j.jchf.2022.03.004

Kotwal S; Perkovic V; Heerspink HJL, 2022, 'Platform Clinical Trials Within Nephrology—Interpreting the Evidence', American Journal of Kidney Diseases, 80, pp. 143 - 146, http://dx.doi.org/10.1053/j.ajkd.2022.01.430

Liao J; Kang A; Xia C; Young T; Di Tanna GL; Arnott C; Pollock C; Krishnan AV; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Levin A; Neal B; Wheeler DC; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ; Smyth B, 2022, 'The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial', Diabetes and Metabolism, 48, pp. 101331, http://dx.doi.org/10.1016/j.diabet.2022.101331

Barraclough JY; Yu J; Figtree GA; Perkovic V; Heerspink HJL; Neuen BL; Cannon CP; Mahaffey KW; Schutte AE; Neal B; Arnott C, 2022, 'Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 24, pp. 1072 - 1083, http://dx.doi.org/10.1111/dom.14671

Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S, 2022, 'Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial', JAMA Internal Medicine, 182, pp. 592 - 602, http://dx.doi.org/10.1001/jamainternmed.2022.0605

Waijer SW; Provenzano M; Mulder S; Rossing P; Persson F; Perkovic V; Heerspink HJL, 2022, 'Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology', Diabetes, Obesity and Metabolism, 24, pp. 983 - 990, http://dx.doi.org/10.1111/dom.14660

Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2022, 'Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial', JAMA - Journal of the American Medical Association, 327, pp. 1888 - 1898, http://dx.doi.org/10.1001/jama.2022.5368

Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL, 2022, 'Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized, Controlled Trials', Circulation, 145, pp. 1460 - 1470, http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057736

Singh AK; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Perkovic V; Solomon S; Wanner C; Waikar SS; Wheeler DC; Wiecek A, 2022, 'Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial', Nephrology Dialysis Transplantation, 37, pp. 960 - 972, http://dx.doi.org/10.1093/ndt/gfab065

Feng Y; Li Q; Finfer S; Myburgh J; Bellomo R; Perkovic V; Jardine M; Wang AY; Gallagher M, 2022, 'A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation', Frontiers in Cardiovascular Medicine, 9, http://dx.doi.org/10.3389/fcvm.2022.840611

Shaman AM; Bain SC; Bakris GL; Buse JB; Idorn T; Mahaffey KW; Mann JFE; Nauck MA; Rasmussen S; Rossing P; Wolthers B; Zinman B; Perkovic V, 2022, 'Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER', Circulation, 145, pp. 575 - 585, http://dx.doi.org/10.1161/CIRCULATIONAHA.121.055459

Waijer SW; Sen T; Arnott C; Neal B; Kosterink JGW; Mahaffey KW; Parikh CR; de Zeeuw D; Perkovic V; Neuen BL; Coca SG; Hansen MK; Gansevoort RT; Heerspink HJL, 2022, 'Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease', Clinical Journal of the American Society of Nephrology, 17, pp. 251 - 259, http://dx.doi.org/10.2215/CJN.08780621

Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ, 2022, 'Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial', American Journal of Kidney Diseases, 79, pp. 244 - 256.e1, http://dx.doi.org/10.1053/j.ajkd.2021.05.005

Liyanage T; Toyama T; Hockham C; Ninomiya T; Perkovic V; Woodward M; Fukagawa M; Matsushita K; Praditpornsilpa K; Hooi LS; Iseki K; Lin MY; Stirnadel-Farrant HA; Jha V; Jun M, 2022, 'Prevalence of chronic kidney disease in Asia: A systematic review and analysis', BMJ Global Health, 7, pp. e007525, http://dx.doi.org/10.1136/bmjgh-2021-007525

See EJ; Bello AK; Levin A; Lunney M; Osman MA; Ye F; Ashuntantang GE; Bellorin-Font E; Benghanem Gharbi M; Davison S; Ghnaimat M; Harden P; Htay H; Jha V; Kalantar-Zadeh K; Kerr PG; Klarenbach S; Kovesdy CP; Luyckx V; Neuen B; O'Donoghue D; Ossareh S; Perl J; Rashid HU; Rondeau E; Syed S; Sola L; Tchokhonelidze I; Tesar V; Tungsanga K; Kazancioglu RT; Wang AYM; Yang CW; Zemchenkov A; Zhao MH; Jager KJ; Caskey F; Perkovic V; Jindal KK; Okpechi IG; Tonelli M; Feehally J; Harris DC; Johnson DW, 2022, 'Availability, coverage, and scope of health information systems for kidney care across world countries and regions', Nephrology Dialysis Transplantation, 37, pp. 159 - 167, http://dx.doi.org/10.1093/ndt/gfaa343

Shah N; Perkovic V; Kotwal S, 2022, 'Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria', Expert Review of Clinical Pharmacology, 15, pp. 827 - 842, http://dx.doi.org/10.1080/17512433.2022.2108402

Young TK; Toussaint ND; Di Tanna GL; Arnott C; Hockham C; Kang A; Schutte AE; Perkovic V; Mahaffey KW; Agarwal R; Bakris GL; Charytan DM; Heerspink HJL; Levin A; Pollock C; Wheeler DC; Zhang H; Jardine MJ, 2022, 'Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial', Journal of Diabetes Research, 2022, http://dx.doi.org/10.1155/2022/9998891

Perkovic V; Tuttle KR; Pergola PE; Mahaffey KW; Patel UD; Ishida JH; Chen F; Crans G; Kustra R; Trivedi M; Heerspink HJL; Rossing P; Kashihara N; Chertow G, 2022, 'A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)', Journal of the American Society of Nephrology, 33, pp. 28 - 28, http://dx.doi.org/10.1681/asn.20223311s128c

Rizk D; Perkovic V; Lafayette RA; Trimarchi H; Barratt J; Carroll K; Tesar V; Zhang H; Suzuki Y; Liew A; Wong MG; Leslie BR; Mathur M; Hafkin J, 2022, 'A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy', Journal of the American Society of Nephrology, 33, pp. 799 - 799, http://dx.doi.org/10.1681/asn.20223311s1799c

Fletcher RA; Arnott C; Rockenschaub P; Schutte AE; Carpenter L; Vaduganathan M; Heerspink HJ; Neal B; Jun M; Rodgers A; Perkovic V; Neuen B, 2022, 'Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials', Hypertension, 79, http://dx.doi.org/10.1161/hyp.79.suppl_1.p201

Koshino A; Oshima M; Arnott CG; Fletcher RA; Perkovic V; Heerspink HJL; Neuen BL, 2022, 'Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD', Journal of the American Society of Nephrology, 33, pp. 673 - 674, http://dx.doi.org/10.1681/asn.20223311s1673c

Rovin BH; Barratt J; Zhang H; Rizk D; Kashihara N; Maes BD; Trimarchi H; Sprangers B; Meier M; Kollins D; Magirr AR; Junge G; Perkovic V, 2022, 'Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy', Journal of the American Society of Nephrology, 33, pp. 33 - 34, http://dx.doi.org/10.1681/asn.20223311s133d

Smeijer JD; Koomen J; Kohan DE; McMurray J; Bakris GL; Correa-Rotter R; Hou FF; Kitzman D; Makino H; Perkovic V; Rossing P; de Zeeuw D; Heerspink HJL, 2022, 'Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD', Journal of the American Society of Nephrology, 33, pp. 116 - 116, http://dx.doi.org/10.1681/asn.20223311s1116c

Ha J; Freedman B; Kelly DM; Neuen BL; Perkovic V; Jun M; Badve S, 2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 33, pp. 297 - 298, http://dx.doi.org/10.1681/asn.20223311s1297c

Singh AK; McCausland FR; Claggett B; Wanner C; Wiecek A; Atkins MB; Carroll K; Perkovic V; McMurray J; Wittes J; Snapinn SM; Blackorby A; Barker T; Dimino TL; Mallett S; Meadowcroft AM; Cobitz AR; Solomon SD, 2022, 'On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D', Journal of the American Society of Nephrology, 33, pp. 631 - 631, http://dx.doi.org/10.1681/asn.20223311s1631d

Neuen BL; Oshima M; Perkovic V; Agarwal R; Arnott C; Bakris G; Cannon CP; Charytan DM; Edwards R; Górriz JL; Jardine MJ; Levin A; Neal B; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Mahaffey KW; Heerspink HJL, 2021, 'Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial', European Heart Journal, 42, pp. 4891 - 4901, http://dx.doi.org/10.1093/eurheartj/ehab497

Singh AK; Carroll K; McMurray JJV; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; DiMino TL; Kler L; Meadowcroft AM; Taft L; Perkovic V, 2021, 'Daprodustat for the treatment of anemia in patients not undergoing dialysis', New England Journal of Medicine, 385, pp. 2313 - 2324, http://dx.doi.org/10.1056/NEJMoa2113380

Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV, 2021, 'Daprodustat for the treatment of anemia in patients undergoing dialysis', New England Journal of Medicine, 385, pp. 2325 - 2335, http://dx.doi.org/10.1056/NEJMoa2113379

Sen T; Li J; Neuen BL; Arnott C; Neal B; Perkovic V; Mahaffey KW; Shaw W; Canovatchel W; Hansen MK; Heerspink HJL, 2021, 'Association between circulating gdf-15 and cardio-renal outcomes and effect of canagliflozin: Results from the canvas trial', Journal of the American Heart Association, 10, pp. e021661, http://dx.doi.org/10.1161/JAHA.121.021661

Feng KY; Li JW; Ianus J; de Zeeuw D; Fulcher GR; Pfeifer M; Matthews DR; Jardine MJ; Perkovic V; Neal B; Mahaffey KW, 2021, 'Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis', Diabetes, Obesity and Metabolism, 23, pp. 2707 - 2715, http://dx.doi.org/10.1111/dom.14525

Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL, 2021, 'The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function A Post Hoc Analysis of the SONAR Randomized Trial', Clinical Journal of the American Society of Nephrology, 16, pp. 1824 - 1832, http://dx.doi.org/10.2215/CJN.07340521

Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2021, 'The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics', American Journal of Nephrology, 52, pp. 827 - 836, http://dx.doi.org/10.1159/000519812

Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D, 2021, 'Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: A prespecified analysis from the SONAR trial', Journal of the American Society of Nephrology, 32, http://dx.doi.org/10.1681/ASN.2021030391

Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M, 2021, 'Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program', Diabetologia, 64, pp. 2402 - 2414, http://dx.doi.org/10.1007/s00125-021-05524-1

Neuen BL; Oshima M; Perkovic V; Arnott C; Bakris G; Cannon CP; Charytan DM; Jardine M; Levin A; Neal B; Pollock C; Wheeler DC; Mahaffey KW; Heerspink HJL, 2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', European Heart Journal, 42, pp. ehab724.2647, http://dx.doi.org/10.1093/eurheartj/ehab724.2647

Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL, 2021, 'Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial', Diabetologia, 64, pp. 2147 - 2158, http://dx.doi.org/10.1007/s00125-021-05512-5

Rahimi K; Bidel Z; Nazarzadeh M; Copland E; Canoy D; Wamil M; Majert J; McManus R; Adler A; Agodoa L; Algra A; Asselbergs FW; Beckett NS; Berge E; Black H; Boersma E; Brouwers FPJ; Brown M; Brugts JJ; Bulpitt CJ; Byington RP; Cushman WC; Cutler J; Devereaux RB; Dwyer JP; Estacio R; Fagard R; Fox K; Fukui T; Gupta AK; Holman RR; Imai Y; Ishii M; Julius S; Kanno Y; Kjeldsen SE; Kostis J; Kuramoto K; Lanke J; Lewis E; Lewis JB; Lievre M; Lindholm LH; Lueders S; MacMahon S; Mancia G; Matsuzaki M; Mehlum MH; Nissen S; Ogawa H; Ogihara T; Ohkubo T; Palmer CR; Patel A; Pfeffer MA; Pitt B; Poulter NR; Rakugi H; Reboldi G; Reid C; Remuzzi G; Ruggenenti P; Saruta T; Schrader J; Schrier R; Sever P; Sleight P; Staessen JA; Suzuki H; Thijs L; Ueshima K; Umemoto S; van Gilst WH; Verdecchia P; Wachtell K; Whelton P; Wing L; Woodward M; Yui Y; Yusuf S; Zanchetti A; Zhang ZY; Anderson C; Baigent C; Brenner BM; Collins R; de Zeeuw D; Lubsen J; Malacco E; Neal B; Perkovic V; Rodgers A; Rothwell P; Salimi-Khorshidi G; Sundström J; Turnbull F; Viberti G; Wang J; Chalmers J; Davis BR, 2021, 'Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis', The Lancet, 398, pp. 1053 - 1064, http://dx.doi.org/10.1016/S0140-6736(21)01921-8

Kang A; Arnold R; Gallagher M; Snelling P; Green J; Fernando M; Kiernan MC; Hand S; Grimley K; Burman J; Heath A; Rogers K; Bhattacharya A; Smyth B; Bradbury T; Hawley C; Perkovic V; Krishnan AV; Jardine MJ, 2021, 'Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial', Clinical Journal of the American Society of Nephrology, 16, pp. 1365 - 1375, http://dx.doi.org/10.2215/CJN.17151120

Wanner C; Cooper ME; Johansen OE; Toto R; Rosenstock J; McGuire DK; Kahn SE; Pfarr E; Schnaidt S; von Eynatten M; George JT; Gollop ND; Marx N; Alexander JH; Zinman B; Perkovic V, 2021, 'Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephroticrange proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial (Clinical Kidney Journal (sfaa225) DOI: 10.1093/ckj/sfaa225)', Clinical Kidney Journal, 14, pp. 2136, http://dx.doi.org/10.1093/ckj/sfab104

Mann JFE; Buse JB; Idorn T; Leiter LA; Pratley RE; Rasmussen S; Vilsbøll T; Wolthers B; Perkovic V, 2021, 'Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis', Diabetes, Obesity and Metabolism, 23, pp. 2058 - 2066, http://dx.doi.org/10.1111/dom.14443

Back to profile page